Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Frailty predicts urinary incontinence, death in older people

Pearl Toh
13 Mar 2018

Frailty is predictive of new-onset urinary incontinence (UI) and death among older adults up to 1 year after hospitalization, a study suggests.

The prospective cohort study involved 210 older adults (mean age 89.4 years, 69.5 percent female) who were admitted to Tan Tock Seng Hospital, Singapore, for an acute medical illness. They were classified as being frail if they showed any three of the five components comprising fatigue, resistance, mobility, illnesses, and weight loss on the FRAIL* scale. The participants were followed up on UI and mortality at 6 and 12 months after hospitalization. [J Am Med Dir Assoc 2018;doi:10.1016/j.jamda.2017.12.103]

New-onset UI was significantly more common among frail vs healthy participants at all time points, from hospitalization (29.7 percent vs 12.3 percent; p=0.025) to 6 months (43.2 percent vs 21.7 percent; p=0.020) and 12 months (56.8 percent vs 33.3 percent, p=0.020) after hospitalization.

Compared with non-frail participants, frail individuals were also more likely to report a history of UI (64.8 percent vs 30.5 percent; p<0.001).

After controlling for age, sex, and illness severity, frailty was independently predictive of incident UI at all time points (adjusted odds ratio [OR], 2.98; p=0.050 at discharge, OR, 2.86; p=0.027 at 6 months, and OR, 2.67; p=0.025 at 12 months).   

“Our study suggests that frailty independently increases the risk of incident UI by 2.7 times … This leads to a strong case that UI may be a result of frailty in some individuals, and a contributor to frailty in others, which ultimately leads to a spiralling cascade of deteriorating frailty status and UI,” said the researchers led by Dr Edward Chong from Tan Tock Seng Hospital.

Having underlying UI was, in turn, associated with a significantly increased risk of mortality over time compared with continent individuals (32.0 percent vs 9.1 percent; p<0.001 at 6 months, and 42.0 percent vs 13.6 percent; p<0.001 at 12 months).

Furthermore, underlying UI was independently predictive of mortality at 6 months (OR, 3.10; p=0.008) and 12 months (OR, 3.41; p=0.002) regardless of frailty status, and after adjusting for age, sex, and illness severity.

“In Singapore, UI has been found to range from 4.6 percent to 14.5 percent. Despite the high prevalence, it is well recognized that many cases of UI remain underreported or are diagnosed at later stages of severity, resulting in inappropriate and/or delayed medical management,” said Chong and co-authors.

“Hence, greater emphasis should be given to identifying and managing UI during hospitalization and after discharge, especially among frail older adults,” they suggested, calling for routine frailty status assessment among older adults admitted to hospitals.

“In addition, high-risk patients should be closely monitored for the possible development of UI following their discharge in order to deliver appropriate medical management early,” added the researchers.

They also suggested future studies be done to explore potential preventive interventions to help reduce the risk of incident IU among hospitalized frail older adults.

Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.